Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one
The present invention relates to an extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one or a pharmaceutically acceptable salt thereof or a hydrate of said pharmaceutically acceptable salt thereof. The invention further relates to the preparation of these extended release formulations and their use in the prevention or treatment of disorders, especially pain and CNS disorders such as depression, anxiety and movement disorders.
1 . An extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one or a pharmaceutically acceptable salt thereof or a hydrate of said pharmaceutically acceptable salt thereof.
2 . An extended release formulation according to claim 1 , characterized in that said pharmaceutically acceptable salt is a monohydrochloride salt.
3 . An extended release formulation according to claim 1 or 2 , characterized in that said hydrate is a monohydrate.
4 . An extended release formulation according to claims 1 - 3 , characterized in that said formulation comprises
a) the active ingredient as defined in claims 1 - 3 ;
b) a hydrophilic cellulose ether or a mixture of two or more hydrophilic cellulose ethers.
5 . An extended release formulation according to claim 4 , characterized in that said one, two or more hydrophilic cellulose ethers is one or more hydroxypropylmethylcelluloses.
6 . An extended release formulation according to claim 5 , characterized in that said formulation comprises a mixture of a low viscosity hydroxypropylmethylcellulose and a medium viscosity methylhydroxy-propylcellulose.
7 . An extended release formulation according to claims 1 - 3 , characterized in that said formulation comprises
a) the active ingredient as defined in claims 1 - 3 ;
b) a starch excipient characterized by a content of long-chain amylose, with a DP of at least 100, of between 20 and 80% by weight based on dry substance, a cold water-solubility of at most 25% by weight and a specific area of at least 1 m 2 /g.
8 . An extended release formulation according to claim 7 , characterized in that the content of long-chain amylose in said starch excipient is between 50 and 80% by weight based on dry substance
9 . An extended release formulation according to claim 8 , characterized in that the content of long-chain amylose in said starch excipient is at least 60% by weight based on dry substance and that the specific area is at least 6 m 2 /g.
10 . A method of treating of CNS disorders or pain, wherein the formulation according to claims 1 - 9 is used.
11 . A method according to claim 10 , characterized that the CNS disorder is selected from the group consisting of depression, anxiety and movement disorders.
12 . A method of reducing the incidence of nausea and vomiting associated with the administration of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one or a pharmaceutically acceptable salt thereof or a hydrate of said pharmaceutically acceptable salt thereof, which method consists of administering an effective amount of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one or a pharmaceutically acceptable salt thereof or a hydrate of said pharmaceutically acceptable salt thereof in an oral extended release pharmaceutical formulation.